Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Optimer Pharmaceuticals
So what: Optimer just reported fantastic sales in the third quarter but still saw a disappointingly large net loss. Impatient investors appear disillusioned by the prognosis that bacterial-diarrhea treatment Dificid won't break even for about three years.
Now what: The market drop notwithstanding, two analyst firms reupped their respective buy ratings on Optimer today with price targets between $19 and $20 per share. Clostridium difficile-related diarrhea doesn't present a huge market like prostate cancer does for Dendreon
Interested in more info about Optimer Pharmaceuticals? Click here to add it to My Watchlist.
Fool contributor Anders Bylund holds no position in any of the companies mentioned. The Motley Fool owns shares of Dendreon. Motley Fool newsletter services have recommended buying shares of Elan. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinion, but we all believe that considering a diverse range of insights makes us better investors. Check out Anders' holdings and bio, or follow him on Twitter and Google+. We have a disclosure policy.